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polyunsaturated fatty acids (LCPUFA) supplementation in erythrocytes, plasma and whole blood of a
previously published dose response study. Methods: a randomized, double-blind, placebo-controlled trial
of parallel design was conducted, whereby pre-menopausal women were randomly assigned to consume
0, 0.35, 0.7 or 1 g/day of supplemental eicosapentaenoic acid (EPA) plus docosahexaenoic acid (DHA).
Fasted blood samples were taken at baseline and after eight weeks intervention. Erythrocyte, plasma and
whole blood fatty acids were extracted using the method of Lepage and Roy and analysed using gas
chromatography. Results: There were significant increases in EPA plus DHA levels in the 0.7 g and 1 g
dose groups, with the highest increase with the 1 g dose notably: in erythrocytes (from 5.69% to 7.59%),
plasma (from 2.94% to 5.48%) and in whole blood (from 3.81% to 6.03%). There was high variability in
response to the supplement in erythrocytes, plasma and whole blood across the different doses.
Conclusion: there is high individual variability in n-3 LCPUFA levels in response to n-3 LCPUFA
supplementation, which should be taken into account in clinical trials using n-3 LCPUFA supplements.
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Abstract: (1) Aim: the aim of this secondary analysis was to report the variability in response to n-3
long chain polyunsaturated fatty acids (LCPUFA) supplementation in erythrocytes, plasma and whole
blood of a previously published dose response study. (2) Methods: a randomized, double-blind,
placebo-controlled trial of parallel design was conducted, whereby pre-menopausal women were
randomly assigned to consume 0, 0.35, 0.7 or 1 g/day of supplemental eicosapentaenoic acid (EPA)
plus docosahexaenoic acid (DHA). Fasted blood samples were taken at baseline and after eight weeks
intervention. Erythrocyte, plasma and whole blood fatty acids were extracted using the method
of Lepage and Roy and analysed using gas chromatography. (3) Results: There were significant
increases in EPA plus DHA levels in the 0.7 g and 1 g dose groups, with the highest increase with the
1 g dose notably: in erythrocytes (from 5.69% to 7.59%), plasma (from 2.94% to 5.48%) and in whole
blood (from 3.81% to 6.03%). There was high variability in response to the supplement in erythrocytes,
plasma and whole blood across the different doses. (4) Conclusion: there is high individual variability
in n-3 LCPUFA levels in response to n-3 LCPUFA supplementation, which should be taken into
account in clinical trials using n-3 LCPUFA supplements.
Keywords: omega-3; variability; erythrocyte; plasma; whole blood

1. Introduction
The omega-3 long chain polyunsaturated fatty acids (n-3 LCPUFA) are comprised of
eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA) and docosahexaenoic acid (DHA). DHA
and arachidonic acid are important fatty acids for neurological development [1,2]. DHA is the most
abundant n-3 LCPUFA in the brain and its role in the brain has been described in a recent review [3].
There are numerous health benefits associated with n-3 LCPUFA, including cardiovascular
disease [4–6], inflammatory disease [7,8] and mental health [9–12]. Harris and von Schacky postulated
that the Omega-3 Index (sum of EPA and DHA expressed as a percentage of total erythrocyte fatty
acids) could be a biomarker for cardiovascular disease risk and that an omega-3 index of greater than
8% is optimal [13]. There is evidence that this omega-3 index biomarker may also be useful in terms of
mental health [9–11,14].
There are many factors that are associated with n-3 LCPUFA levels [15]. Factors positively
associated with the n-3 LCPUFA levels are age and sex (women less than 50 years of age). Factors
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negatively associated with the n-3 LCPUFA levels are: genetics, BMI (if erythrocyte EPA and DHA is
less than 6%), smoking and alcohol. Therefore, the International Society for the Study of Fatty Acids
and Lipids (ISSFAL) has released a position statement, which states that any type of n-3 LCPUFA
research should measure n-3 LCPUFA levels in the blood [16].
There have been numerous trials investigating the effect of n-3 LCPUFA on various
outcome measures, but only a few have reported the large individual variability in response to
supplementation [17–20].
Therefore, the aim of this study was to report the variability in response to n-3 LCPUFA
supplementation, as a secondary analysis of a dose response study.
2. Materials and Methods
2.1. Study Participants
Participants in this study were a subset of 53 premenopausal women reported elsewhere with
respect to the effect of DHA supplementation on plasma triglycerides and lipoproteins [21]. This cohort
of 45 participants (85% of total sample) represents those for whom data on erythrocyte, plasma and
whole blood fatty acid compositions were available for secondary analysis.
Healthy premenopausal women with mildly elevated triglycerides (>1.0 mmol/L) and regular
menstrual cycles (28–32 days) were recruited for this study, conducted at the University of Wollongong,
Australia. Exclusion criteria included age <18 or >40 years, consumption of fish oil supplements, and
known existing cardiovascular disease. Subjects who completed the trial were required to achieve
a capsule compliance rate of >90% on the basis of self-report and excess capsule count, and a body
weight change of ≤5% from baseline. The study protocol was approved by the Human Research Ethics
Committee of the University of Wollongong (HE06/317), and the research has therefore been performed
in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later
amendments. Written informed consent was obtained from the participant prior to inclusion in the
study (Australian and New Zealand Clinical Trial Registration ID: ANZCTRN12607000566437).
2.2. Study Design
A randomized, double-blind, placebo-controlled trial of parallel design was conducted, whereby
subjects were randomly assigned to consume 0, 350, 700, or 1000 mg/day of supplemental EPA plus
DHA for two menstrual cycles (approximately 8 weeks). Randomization was controlled for age, BMI,
and contraceptive pill use.
DHA was provided in the form of HiDHA™ tuna oil (500 mg sized capsules supplied by Nu-Mega
Ingredients, Australia). Subjects consumed six capsules daily, with the four different doses achieved
by varying the proportion of active (HiDHA™ tuna oil) and placebo (Sunola oil, 500 mg) capsules for
each dose group. Each tuna oil capsule provided 35 mg EPA and 135 mg DHA, whereas each placebo
capsule provided 355 mg monounsaturated fatty acids (MUFA), 55 mg saturated fatty acids (SFA), and
14 mg PUFA (no n-3 LCPUFA).
Daily doses of capsules were provided in individual zip-lock bags, and an excess of these bags was
distributed to participants. Participants also kept a diary to record daily capsule intake and menstrual
cycle status. Compliance with capsule consumption was assessed using the diary records and excess
capsule count, and confirmed by measurement of erythrocyte n-3 LCPUFA levels.
2.3. Clinic Visits
Study participants monitored their menstrual cycle and reported commencement of menses,
such that they attended the research clinic on two consecutive mornings between days 3–5 of their
menstrual cycle, both at baseline and after approximately 8 weeks (two menstrual cycles) of DHA
supplementation. Height (baseline only), body weight, blood pressure and fasted blood samples were
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collected at baseline and at the end of the intervention. Blood pressure was measured in triplicate at all
clinic visits, using an automatic blood pressure monitor.
2.4. Dietary Intake Analysis
Comprehensive information on the habitual intakes of PUFA, including individual n-3 LCPUFA,
was obtained using a validated electronic PUFA food frequency questionnaire [22]. The Victorian
Anti-Cancer Council Food Frequency Questionnaire was administered to determine the macro- and
micro-nutrient intake levels of participant’s whole diets. Participants were instructed to avoid dietary
changes for the study duration.
2.5. Blood Sample Collection and Processing
Following an overnight fast (>10 h), venous blood was collected into ethylenediaminetetraacetic
acid (EDTA) tubes on two consecutive days (36 mL on Day 1; 9 mL on Day 2) at baseline and
post-intervention. An aliquot of whole blood was stored at −80 ◦ C and the remaining blood samples
were subjected to centrifugation 2000g at 4 ◦ C for 10 minutes, to separate plasma from erythrocytes.
Aliquots of erythrocytes, plasma and whole blood were stored at −80 ◦ C for the analysis of fatty acids;
fatty acids were recorded once both at baseline and post-intervention.
2.6. Fatty Acid Analysis
Fatty acid analyses of erythrocytes, plasma and whole blood were performed on total lipids,
without separation of the different lipid classes. The fatty acid profiles of erythrocytes were determined
using standard methods previously reported [23]. Briefly, erythrocyte aliquots (400 µL) were thawed
and re-suspended in a TRIS buffer (10 mM Bis Tris, 2 mM EDTA Na2, pH 7.2), at room temperature for
30 min. The samples were then spun in an ultracentrifuge at 315,000 g for 30 min at 4 ◦ C (Beckman L-80
OPTIMA, Indianapolis, IN, USA) to pellet erythrocyte membranes. Upon removal of the supernatant,
the erythrocyte membrane pellet was re-suspended in 200 µL of distilled water. A fixed volume
(150 µL) of the erythrocyte membrane suspension was used for the direct transesterification of fatty
acids [24], using heneicosanoic acid as the internal standard, as described below.
Preparation of fatty acid methyl esters (FAME) from plasma fatty acids was performed using
the one-step direct transesterification method of Lepage and Roy [24]. During this process, only the
complex lipids will be transmethylated, and the free fatty acids will be methylated. Briefly, 200 µL
plasma was added to Teflon-lined 10 mL glass screw-cap tubes, followed by the addition of 2 mL of
methanol/toluene (4:1 v/v) containing BHT as an antioxidant (0.01% w/v), and 200 µL of 0.2 mg/mL
internal standard solution (heneicosaenoic acid, 21:0), Sigma Aldrich, Castle Hill, Australia). Acetyl
chloride (200 µL) as a catalyst was then added slowly using a positive displacement pipette, while
vortexing tubes. Sealed tubes were then heated to 100 ◦ C for 1 h on a heat block (Thermoline BTC-9090
Dry Block Heater, Thermoline Scientific Equipment, Smithfield, Australia). Tubes were then cooled,
followed by a slow addition of 5 mL of 6% potassium carbonate while vortexing. Tubes were then
subjected to centrifugation for 10 min at 2000 g and 4 ◦ C (Rotina 46R, Hettich Zentrifugen, Rotanta 460
Centrifuge, GMI In., Minnesota, MN, USA). The supernatant (toluene phase) was then collected and
stored in a small glass autosampler vial (with insert), for gas chromatography analysis. Whole blood
fatty acids were extracted as outlined above for plasma fatty acids.
FAME were analysed by injecting 1 µL of each sample into a gas chromatograph (GC 17A Shimadzu,
Columbia, MD, USA) equipped with an autoinjector, 30 m FAME capillary column (0.25 mm internal
diameter, Varian, Palo Alto, CA, USA), and flame ionization detector. Hydrogen was used as the
carrier gas. Fatty acid peaks were identified by comparison to known mixed standards (Nu-Chek
Prep, Minnesota, USA; Sigma Aldrich, Castle Hill, Australia), and quantified using Shimadzu software
(Class-VP 7.2.1 SP1, Kyoto, Japan). The data is presented as percentage of total erythrocyte fatty acids,
plasma fatty acids and whole blood fatty acids.
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2.7. Statistical Analysis
Statistical analyses were conducted using JMP 5.1 statistical software (SAS, Cary, NC, USA). The
Shapiro–Wilk test was used to assess whether each variable fit a normal distribution. Non-normal
variables were subsequently transformed using the log10 algorithm prior to statistical analyses. Baseline
and post-supplementation differences between dose groups were examined using a one-way ANOVA
with Tukey’s honest significant difference (HSD) analysis. Inter-individual variability in response
(i.e., the coefficient of variation) was calculated per dose group as the standard deviation divided by
the mean for erythrocytes, plasma and whole blood. A value of p < 0.05 was considered statistically
significant for all analyses.
3. Results
3.1. Study Participants Characteristics
There were no significant differences between dose groups in age, body mass index (BMI), systolic
or diastolic blood pressures (Table 1). Blood pressures and BMI were within the healthy range, with
the latter being borderline overweight on average.
Table 1. Subject characteristics (n = 45) (values mean and standard deviation (SD)).
Whole Group
(n = 45)
Age (years)
SBP (mmHg)
DBP (mmHg)
BMI

0 g/day
(n = 11)

0.35 g/day
(n = 14)

0.7 g/day
(n = 12)

1 g/day
(n = 8)

Mean

SD

Mean SD

Mean SD

Mean SD

Mean SD

26.5
114
71
25

6.4
9.1
8.4
5.1

26.8
113
70
23

26.8
116
72
25

24.7
116
72
25

28.5
109
71
25

6.8
7.0
7.2
3.1

6.7
8.8
8.5
5.3

5.3
12.0
11.2
6.2

7.4
7.0
5.3
5.4

p Value

0.63
0.35
0.91
0.68

Abbreviations: BMI: Body mass index; DBP: Diastolic blood pressure; SD: Standard deviation; SBP: Systolic
blood pressure.

3.2. Dietary Intakes and Compliance to Treatment
Dietary macronutrient and fatty acid intakes of all participants combined, and for each dose
group, are displayed in Table 2. Total PUFA intake in the 0.35 g/day group was significantly greater
than the placebo group, explained by a greater intake of linoleic acid. It appeared this was due to an
unusually high consumption of oils by one participant in that dose group, and of nuts by another. The
groups did not differ in their habitual dietary intakes of any other PUFA, including EPA and DHA.
Table 2. Baseline dietary intakes of macronutrients and fatty acids, as measured by food frequency
questionnaire (median (IQR), n = 45).
Whole Group

Placebo Group

(n = 45)

0 g/day
(n = 11)

0.35 g/day
(n = 14)

Doses of DHA
0.7 g/day
(n = 12)

1 g/day
(n = 8)

Median (IQR)

Median (IQR)

Median (IQR)

Median (IQR)

Median (IQR)

Energy (kJ/day)

6165
(4979, 8021)

6412
(5173, 8029)

5862
(4568, 7618)

7109
(5245, 8969)

5187
(3774, 6731)

0.28

Protein (g/day)

79 (59, 96)

86 (64, 101)

72 (57, 95)

88 (58, 112)

64 (55, 87)

0.50

Carbohydrate
(g/day)

163 (134, 201)

172 (156, 195)

146 (117, 200)

192 (141, 241)

149 (102, 176)

0.12

Total fat (g/day)

59 (44, 77)

61 (44, 81)

59 (45, 78)

67 (45, 77)

43 (31, 62)

0.43

p Value
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Table 2. Cont.

SFA (g/day)

Whole Group

Placebo Group

(n = 45)

0 g/day
(n = 11)

0.35 g/day
(n = 14)

0.7 g/day
(n = 12)

1 g/day
(n = 8)

Median (IQR)

Median (IQR)

Median (IQR)

Median (IQR)

Median (IQR)

24 (16, 28)

24 (20, 28)

24 (18, 31)

24 (18, 32)

15 (12, 24)

0.38
0.47
5 of 15
0.01

MUFA (g/day)
22 (15, 27)
23 (14, 33)
Nutrients 2020, 12,# x FOR PEER REVIEW
9.4 (7.4, 13.3)
7.5 (5.3, 10.5) *
PUFA (g/day)

Doses of DHA

21 (17, 28)

25 (15, 27)

16 (11, 23)

13.3 (8.3, 18.4)

9.6 (7.6, 11.3)

8.8 (6.3, 13.4)

p Value

7.5 (6.3, 11.3)
6.4 (4.8, 8.3) *
11.2 (7.3, 15.8)
7.9 (6.2, 9.3)
6.91 (5.25, 11.1)
0.01
LA
(g/day) #
MUFA (g/day)
22 (15, 27)
23 (14, 33)
21 (17, 28)
25 (15, 27)
16 (11, 23)
0.47
#
0.86 (0.64, 1.44)
0.77 (0.59, 0.86)
1.00 (0.62,
1.73) 0.91 (0.69, 1.39) 0.84 (0.59, 1.43)
0.35
ALA (g/day)
13.3
(8.3,
PUFA (g/day) #
9.4 (7.4, 13.3)
7.5 (5.3, 10.5) *
9.6 (7.6, 11.3)
8.8 (6.3, 13.4)
0.01
18.4)
0.15 (0.12, 0.23)
0.15 (0.09, 0.20)
0.16 (0.13,
0.33) 0.15 (0.09, 0.21) 0.16 (0.11, 0.24)
0.08
AA (g/day) #
11.2 (7.3,
6.91 (5.25,
(g/day) ##
(6.2,
9.3)
0.01
1207.5
(51,(6.3,
178)11.3) 806.4
(27,(4.8,
122)8.3) * 123 (65, 195)
907.9(55,
212)
153 (55, 207)
0.60
EPALA
(mg/day)
15.8)
11.1)
#
89 (54,
149)
87 (41, 113)
87 (58,
930.91
(52, (0.69,
150)
130.84
(56,(0.59,
178)
0.18
DPA (mg/day)
0.86
(0.64,
1.00 178)
(0.62,
ALA (g/day) #
0.77 (0.59, 0.86)
0.35
1.73)
1.39)
1.43)
117 (56,1.44)
242)
117 (21, 186)
110 (56,
249)
136 (77,
237)
145 (40,
392)
0.28
DHA (mg/day) #
0.15 (0.12,
0.16 (0.13,
0.15 (0.09,
0.16 (0.11,
AA
(g/day) #
0.15 (0.09, 0.20)
0.08
n-3
LCPUFA
0.23)
0.33)
0.21)
0.24)700)
338
(186,
546)
255
(96,
425)
368
(197,
600)
279
(203,
628)
445
(160,
0.21
(mg/day) #
#
EPA (mg/day)
120 (51, 178)
80 (27, 122)
123 (65, 195)
90 (55, 212)
153 (55, 207)
0.60
Abbreviations:
AA:89Arachidonic
acid;
ALA:
EPA:
Eicosapentaenoic
acid; DPA:
DPA
(mg/day) #
(54, 149)
87 (41,
113) Alpha-linolenic
87 (58, 178)acid; 93
(52, 150)
13 (56, 178)
0.18
Docosapentaenoic
acid; DHA: Docosahexaenoic acid; IQR: Interquartile range; LA: Linoleic acid; LCPUFA:
#
DHA
117 (56, fatty
242) acids;117
(21, 186)
110 (56, 249)
136 PUFA:
(77, 237)
145 (40, 392)
0.28
Long(mg/day)
chain polyunsaturated
MUFA:
Monounsaturated
fatty acids;
Polyunsaturated
fatty acids;
#
n-3
LCPUFA
SFA: Saturated fatty acids.
questtionnaire;
* Significantly
different
from placebo
group
338 (186,Data
546)from PUFA
255 (96,
425)
368 (197,
600)
279
(203, 628)
445 (160,
700)(p < 0.05)
0.21
#
(mg/day)
using
one-way
ANOVA followed by post-hoc Tukey-Kramer HSD.

Abbreviations: AA: Arachidonic acid; ALA: Alpha-linolenic acid; EPA: Eicosapentaenoic acid; DPA:
Docosapentaenoic
acid;
acid; did
IQR:not
Interquartile
range; LA: However,
Linoleic acid;
For
EPA and DPA,
the DHA:
mean Docosahexaenoic
and median intakes
differ substantially.
for the
LCPUFA:
Long
chain
polyunsaturated
fatty
acids;
MUFA:
Monounsaturated
fatty
acids;
PUFA:
study cohort combined, the median DHA intake was approximately one third lower than the mean
# Data from PUFA questtionnaire; *
fattywas
acids;
fatty acids. of
intakePolyunsaturated
(0.179 g/day). This
dueSFA:
to theSaturated
skewed distribution
fish and seafood intake, whereby some
Significantly
different
from
placebo
group
(p
<
0.05)
using
one-way
ANOVA followed by post-hoc
participants reported regularly consuming no fish or seafood.
Tukey-Kramer HSD.

All participants consumed ≥90% of their allocated capsules and therefore all participants
were compliant.
3.3. Variability of Baseline Dietary EPA Plus DHA (g/day) and Erythrocyte EPA Plus DHA (% of Total
FattyVariability
Acids) of Baseline Dietary EPA Plus DHA (g/day) and Erythrocyte EPA Plus DHA (% of Total
3.3.
Fatty Acids)
Figure 1 shows the high variability of erythrocyte EPA plus DHA levels, prior to
supplementation
across
a wide
range of
intakes.
ofprior
variation
of erythrocyte
Figure 1 shows
the high
variability
of dietary
erythrocyte
EPA The
pluscoefficient
DHA levels,
to supplementation
EPA plus
DHA
levels
is high intakes.
(0.22). The
was 0.32
blood
across
a wide
range
of dietary
Thecoefficient
coefficientofofvariation
variationofofplasma
erythrocyte
EPAand
pluswhole
DHA levels
was
0.29.
is high (0.22). The coefficient of variation of plasma was 0.32 and whole blood was 0.29.

Figure 1. Dietary eicosapentaenoic acid (EPA) plus docosahexaenoic acid (DHA) intakes (g/day) versus
Figure 1. Dietary eicosapentaenoic acid (EPA) plus docosahexaenoic acid (DHA) intakes (g/day)
erythrocyte EPA plus DHA (expressed as % of total fatty acids) from all participants (n = 45) at baseline.
versus erythrocyte EPA plus DHA (expressed as % of total fatty acids) from all participants (n = 45)
at baseline.

3.4. Fatty Acid Response to n-3 LCPUFA Supplementation
There were no significant differences in the placebo group between baseline and postsupplementation fatty acids in erythrocytes (p = 0.68), plasma (p = 0.70) and whole blood (p = 0.67).
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3.4. Fatty Acid Response to n-3 LCPUFA Supplementation
There were no significant differences in the placebo group between baseline and
post-supplementation fatty acids in erythrocytes (p = 0.68), plasma (p = 0.70) and whole blood
(p = 0.67).
There were significant increases in erythrocyte, plasma and whole blood fatty acids in the groups
supplemented with 0.7 g and 1 g/day, with the greatest increase with the 1 g dose (Table 3).
Table 3. Erythrocyte, plasma and whole blood n-3 LCPUFA (mol %), at baseline and after
supplementation with 0-1000 mg/day EPA plus DHA from DHA-rich tuna oil (n = 45) (values
are median (IQR).
0 g/day (n = 11)

0.35 g/day (n = 14)

0.7 g/day (n = 12)

1 g/day (n = 8)

0 Weeks

8 Weeks

0 Weeks

8 Weeks

0 Weeks

8 Weeks

0 Weeks

8 Weeks

EPA

0.48
(0.40, 0.58)

0.50 a
(0.33, 0.71)

0.52
(0.44, 0.72)

0.54 a
(0.43, 0.64)

0.63
(0.59, 0.70)

0.71 a
(0.67, 0.81)

0.89
(0.40, 1.19)

1.14 b
(0.76, 1.37)

DHA

4.38
(3.57, 5.54)

3.97 a
(3.46, 4.95)

4.12
(3.48, 4.78)

4.94 a
(4.48, 5.25)

4.47
(4.03, 4.82)

5.70 b
(5.55, 6.24)

4.80
(3.63, 5.64)

6.27 b
(5.93, 7.15)

EPA+DHA

4.82
(3.97, 5.99)

4.68 a
(3.86, 5.57)

4.74
(3.85, 5.32)

5.44 a
(4.98, 5.75)

5.10
(4.62, 5.60)

6.47 b
(6.22, 6.87)

5.69
(4.00, 6.83)

7.59 c
(6.70, 8.38)

EPA

0.54
(0.49, 0.76)

0.65 a
(0.47, 0.85)

0.71
(0.56, 0.81)

0.71 a
(0.57, 0.84)

0.73
(0.62, 0.86)

1.07 b
(0.87, 1.33)

0.82
(0.57, 1.44)

1.64 c
(1.10, 2.45)

DHA

1.92
(1.33, 2.15)

1.54 a
(1.39, 1.91)

1.82
(1.47, 2.00)

2.32 a
(1.98, 2.47)

1.61
(1.43, 2.12)

3.14 b
(2.71, 3.41)

2.24
(1.52, 2.70)

3.76 c
(3.18, 4.45)

EPA+DHA

2.59
(1.88, 2.70)

2.33 a
(1.97, 2.76)

2.52
(2.14, 2.74)

3.06 a
(2.79, 3.35)

2.24
(2.10, 3.15)

4.30 b
(3.60, 4.88)

2.94
(2.07, 4.13)

5.48 c
(4.34, 6.68)

EPA

0.59
(0.48, 0.68)

0.63 a
(0.47, 0.84)

0.66
(0.50, 0.77)

0.68 a
(0.54, 0.89)

0.72
(0.60, 0.85)

0.90 a
(0.74, 1.14)

0.88
(0.59, 1.36)

1.42 b
(1.03, 2.17)

DHA

2.78
(2.3, 3.2)

2.37 a
(2.07, 2.96)

2.56
(2.16, 2.87)

3.28 a,b
(2.80, 3.41)

2.57
(2.13, 2.84)

4.05 b
(3.61, 4.53)

3.05
(2.10, 3.40)

4.41 b,c
(3.88, 5.56)

EPA+DHA

3.42
(2.80, 3.87)

3.04 a
(2.71, 3.81)

3.17
(2.86, 3.50)

3.94 a,b
(3.55, 4.17)

3.32
(2.79, 3.57)

4.79 b
(4.52, 5.67)

3.81
(2.78, 4.73)

6.03 c
(4.91, 7.21)

Erythrocyte

Plasma

Whole blood

No significant differences between baseline levels across the 4 groups, except 1 g group at 0 weeks, is significantly
higher than placebo at 0 weeks (p = 0.049). a,b,c Different letters denote significant differences between the groups
post supplementation, all p < 0.0001. Abbreviations: EPA: Eicosapentaenoic acid; DHA: Docosahexaenoic acid.
Whole blood contains erythrocytes, platelets and plasma.

As expected, the 3 measures of fatty acid assessments (erythrocyte, plasma and whole blood)
were highly correlated. The correlations of erythrocyte EPA plus DHA (expressed as percent of total
fatty acids) with plasma and whole blood at baseline were 0.87 and 0.88, respectively. The correlation
of plasma EPA plus DHA (expressed as percent of total fatty acids) with whole blood at baseline was
0.93. The correlations of erythrocyte EPA plus DHA (expressed as percent of total fatty acids) with
plasma and whole blood post-intervention were 0.90 and 0.90, respectively. The correlation of plasma
EPA plus DHA (expressed as percent of total fatty acids) with whole blood post-intervention was 0.97.
Including BMI in the model, the model improved slightly, explaining up to 55% to 58% of the
variance of EPA plus DHA in the blood (erythrocytes, plasma and whole blood), whereas the BMI
in addition to dietary intakes of EPA plus DHA at baseline explained between 26% to 32% (Table 4).
In model 2, the correlation with BMI was negative so people with a higher BMI had lower EPA plus
DHA levels.
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Table 4. Correlations of dietary EPA plus DHA (mg/day) with blood levels of EPA plus DHA, at
baseline and post-intervention.
Dietary Intake of EPA Plus DHA
(g/day) Baseline
Model 1
EPA plus DHA in erythrocytes
(% of total fatty acids)
EPA plus DHA in plasma (%
of total fatty acids)
EPA plus DHA in whole blood
(% of total fatty acids)
Model 2
(includes baseline BMI)
EPA plus DHA in erythrocytes
(% of total fatty acids)
EPA plus DHA in plasma (%
of total fatty acids)
EPA plus DHA in whole blood
(% of total fatty acids)

Dietary Intake of EPA Plus DHA
(g/day) Post-Intervention

R2 adjusted

p value

R2 adjusted

p value

0.25

0.0003

0.48

<0.0001

0.21

0.0009

0.50

<0.0001

0.20

0.0016

0.48

<0.0001

R2 adjusted

p value

R2 adjusted

p value

0.28

0.0003

0.55

<0.0001

0.32

<0.0001

0.58

<0.0001

0.26

0.0010

0.58

<0.0001

Dietary intake of EPA plus DHA post-intervention explains approximately 50% of the variance of EPA plus DHA in
the blood (erythrocytes, plasma and whole blood), whereas it only explained up to 25% of the variance at baseline.

3.5. Individual Response to n-3 LCPUFA Supplementation
The individual’s response to supplementation is highly variable. Figure 2 shows the individual
persons’ EPA and DHA (as % of total fatty acids), supplementation with placebo in erythrocytes
(Figure 2A), plasma (Figure 2B) and whole blood (Figure 2C) with pre-supplementation (in
dark grey) and post-supplementation (in light grey). The range of post-supplementation minus
pre-supplementation for erythrocyte, plasma and whole blood was −0.96 to 1.13, −0.85 to 0.19 and
−0.45 to 0.33 for erythrocyte, plasma and whole blood, respectively.
Figure 3 shows the individual person’s EPA and DHA (as % of total fatty acids) supplementation
with 0.35 g n-3 LCPUFA per day in erythrocytes (Figure 3A), plasma (Figure 3B) and whole blood
(Figure 3C), with pre-supplementation (in dark grey) and post-supplementation (in light grey). The
range of post-supplementation minus pre-supplementation for erythrocyte, plasma and whole blood
was −1.27 to 1.75, −0.53 to 1.13 and −0.07 to 2.56 for erythrocyte, plasma and whole blood, respectively.
Figure 4 shows the individual persons’ EPA and DHA (as % of total fatty acids) supplementation,
with 0.7 g n-3 LCPUFA per day in erythrocytes (Figure 4A), plasma (Figure 4B) and whole blood
(Figure 4C), with pre-supplementation (in dark grey) and post-supplementation (in light grey). The
range of post-supplementation minus pre-supplementation for erythrocyte, plasma and whole blood
was −1.3 to 2.52, −1.35 to 3.28 and −1.71 to 2.9 for erythrocyte, plasma and whole blood, respectively.
Figure 5 shows the individual persons’ EPA and DHA (as % of total fatty acids) supplementation
with 1.0 g n-3 LCPUFA per day in erythrocytes (Figure 5A), plasma (Figure 5B) and whole blood
(Figure 5C) with pre-supplementation (in dark grey) and post-supplementation (in light grey). The
range of post-supplementation minus pre-supplementation for erythrocyte, plasma and whole blood
was −0.55 to 4.23, 0.27 to 3.85 and 0.34 to 3.46 for erythrocyte, plasma and whole blood, respectively.
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Figure 4 shows the individual persons’ EPA and DHA (as % of total fatty acids)
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and whole blood was −1.3 to 2.52, −1.35 to 3.28 and −1.71 to 2.9 for erythrocyte, plasma and whole
blood, respectively.
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Figure 5 shows the individual persons’ EPA and DHA (as % of total fatty acids) supplementation
with 1.0 g n-3 LCPUFA per day in erythrocytes (Figure 5A), plasma (Figure 5B) and whole blood
(Figure 5C) with pre-supplementation (in dark grey) and post-supplementation (in light grey). The
range of post-supplementation minus pre-supplementation for erythrocyte, plasma and whole blood
was −0.55 to 4.23, 0.27 to 3.85 and 0.34 to 3.46 for erythrocyte, plasma and whole blood, respectively.
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but there were no correlations in plasma (r = −0.01, p = 0.54) and whole blood (r = 0.01, p = 0.27).
4. Discussion
This study is a secondary analysis of a dose response study on n-3 LCPUFA supplementation
and plasma lipids which has already been published [21]. In this secondary analysis, we have shown
high individual variability in response to n-3 LCPUFA supplementation.
All participants included in the analysis were compliant (capsule count) with the consumption
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4. Discussion
This study is a secondary analysis of a dose response study on n-3 LCPUFA supplementation and
plasma lipids which has already been published [21]. In this secondary analysis, we have shown high
individual variability in response to n-3 LCPUFA supplementation.
All participants included in the analysis were compliant (capsule count) with the consumption
of the allocated capsules and therefore the individual variability in response to supplementation is
unlikely to be attributed to the lack of compliance.
It has previously been reported that there is considerable variability in the erythrocyte EPA+DHA
levels in response to n-3 supplementation [18]. Others have also reported that this happens in plasma
and platelets [25] and neutrophils [26]. Certainly, plasma EPA and DHA levels are influenced by recent
dietary intakes of EPA and DHA, whereas it is widely believed that erythrocyte levels of EPA and DHA
are indicative of longer term status and reflect body tissues levels [27,28]. Despite this belief, several
studies have shown that erythrocyte fatty acid compositions can be altered in less than seven days,
by n-6 PUFA [29] and n-3 LCPUFA [30], perhaps through the exchange of fatty acids from plasma to
erythrocytes and platelets. Therefore, it is likely that variability in response to supplementation seen in
one blood compartment would be seen in all (erythrocytes, plasma and whole blood).
Studies have shown that the biological variability was lower in erythrocytes than in plasma using
kinetic studies [31,32]. Other studies reveal that the extent of response to the supplements range from
0.4% to 6% increases to no increase, and in some cases decreases in the levels of EPA+DHA [18,25]. Since
these reports of variability have been reported from different laboratories and in different countries, it
is possible to rule out methodological issues and ethnicity as likely causes. One possible explanation
for the variability is that people with different BMIs respond differently to the same dose of n-3 PUFA,
leading to the idea that doses of n-3 should be adjusted for weight or BMI [33]. While this is a plausible
explanation, it would not account for decreases in erythrocyte EPA+DHA after n-3 supplementation.
The most likely explanation for such decreases is that the subjects failed to consume their capsules.
Another possibility for the variation in the increases on EPA+DHA in erythrocytes is that there are
differences between people in the uptake of n-3 PUFA into erythrocytes. To our knowledge, the
mechanisms involved in the uptake of PUFA into erythrocytes have not been firmly established. There
is evidence for the passive exchange of phospholipids between plasma and erythrocytes which allows
renewal of erythrocyte PC [34], as well as acylation of lysoPC for uptake of free fatty acids from
plasma [35]. This latter pathway would likely involve up to two enzymes, including lipoprotein lipase
action on plasma lipoproteins to produce free fatty acids and then acylation of lysoPC to form PC. It is
entirely possible that the expression of any one or both of those enzymes could be regulated differently
in different subjects, in other words, under genetic control through single-nucleotide polymorphisms
(SNPs).
The novelty of our current study is that we compared erythrocytes, plasma and whole blood from
the same individuals. The individual variability in this study is high and comparable to previous
studies where similar coefficients of variation (0.21) have been reported [17].
There are non-dietary factors that are associated with blood n-3 LCPUFA levels [15], including
gender, age, alcohol consumption, smoking and BMI. As the original study was designed for
pre-menopausal women, we only had one gender in this study and therefore cannot comment
on the effect of gender in this study. Age had no effect (results not shown) possibly due to the narrow
age range (18–39 years) in this study. Alcohol consumption had no effect (results not shown) and in
the original study, smoking status was not collected. In terms of BMI, five previous studies showed
a negative association of BMI and EPA plus DHA levels, whilst six previous studies showed no
association [15]. In this study, dietary intake of EPA and DHA explained approximately 50% of the
variance in blood EPA plus DHA levels. In our model 2, when we added BMI, it increased the variance
of EPA plus DHA to 55%–58%.
In this small study, it appeared that the lower the pre-supplementation EPA plus DHA levels,
the greater the increase in EPA plus DHA levels, especially as measured in erythrocyte EPA plus
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DHA, for reasons that are not clear. Published data in this context are limited, but our results are
consistent with at least one previous report, which showed that as individuals baseline n-3 LCPUFA
increased, the treatment-associated changes decreased [36]. Apart from diet and baseline EPA and
DHA levels, the variability in response could be due to differences in digestion of the supplements,
possibly due to differences in pancreatic lipase activity and/or gastrointestinal transport of lipids [37,38].
Certainly, consuming n-3 LCPUFA supplements with sufficient amounts of fat in the meal has the
greatest bioavailability effect (up to three times higher [39], as fat in the meal stimulates fat digestion
and hence increases the bioavailability of n-3 LCPUFA) [39]. Another possibly for some of these data
is that there are some individuals who are non-responders to n-3 LCPUFA supplementation. It is
possible that non-responders have gene-related impaired mechanisms for the uptake of n-3 LCPUFA
from plasma lipoproteins. This lack of response was reported previously by Köhler et al. [17,18] An
alternate explanation is that some individuals do not take their capsules for the study period, however
this should show up on capsule recounts.
These results presented here emphasise the need to measure baseline blood EPA and DHA levels
and post-supplementation levels in any trials which attempt to test the effect of supplemental EPA
plus DHA on biological/physiological outcomes. Therefore, in studies which aim to assess the effect
of n-3 LCPUFA, it is important to consider the guidelines offered by the ISSFAL Official Statement
Number 6: The importance of measuring blood omega-3 long chain polyunsaturated fatty acid levels
in research [16].
These results also support using an individualised dose of EPA and DHA in clinical trials, such
that the target levels are reached prior to evaluating the outcomes of the trial [18,40].
Strengths and Limitations
A strength of this study is the novelty in terms of reporting the individual variability in response
to various doses of n-3 LCPUFA supplementation in erythrocytes, plasma and whole blood in the
same individuals. Another strength of the study was controlling blood collection according to menses,
minimizing the effects of hormones on fatty acid metabolism.
The limitations of this study include a small sample size and relatively short duration of
intervention, although others have shown that an eight week intervention is long enough to increase
erythrocyte n-3 LCPUFA [41] and we have shown significant results. However, it is premature to
assume that these results apply to a larger sample size in Australia or in other countries, or in different
ethnic groups. Another limitation is that this study was conducted only in women of childbearing age.
5. Conclusions
There is high individual variability in response to n-3 LCPUFA supplementation in women of
child-bearing age. Further studies in different populations examining whether variations in response
to supplements are consistent for individuals are needed, to fully understand the individual responses
to n-3 LCPUFA supplementation.
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Abbreviations
n-3 LCPUFA
EPA
DPA
DHA
LA
AA
ALA
EDTA
FAME
BMI
SBP
DBP
IQR
L MUFA
PUFA
SFA

Omega-3 long chain polyunsaturated fatty acids
eicosapentaenoic acid
docosapentaenoic acid
docosahexaenoic acid
Linoleic acid
Arachidonic acid
Alpha-linolenic acid
ethylenediaminetetraacetic acid
fatty acid methyl esters
body mass index
systolic blood pressure
diastolic blood pressure
Interquartile range
Monounsaturated fatty acids
Polyunsaturated fatty acids
Saturated fatty acids
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